PDCD1 and melanoma: CV8102 is being explored as a single agent, administered via intratumoral injection, and in combination with a PD-1 antibody in a phase 1 study (NCT03291002) of patients with advanced melanoma, cutaneous squamous cell carcinoma (cSCC), SCCHN, or adenoid cystic carcinoma.